scispace - formally typeset
K

Kouki Inai

Researcher at Hiroshima University

Publications -  158
Citations -  8775

Kouki Inai is an academic researcher from Hiroshima University. The author has contributed to research in topics: Lung cancer & Carcinoma. The author has an hindex of 39, co-authored 158 publications receiving 7398 citations.

Papers
More filters
Journal ArticleDOI

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Peter Goldstraw, +142 more
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
Journal ArticleDOI

Telomerase Activity in Small-Cell and Non–Small-Cell Lung Cancers

TL;DR: The subset of non-small-cell lung cancers that exhibits only low or undetectable levels of telomerase activity may contain primarily mortal cancer cells, which are likely to consist mainly of immortal cells.
Journal ArticleDOI

The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

William D. Travis, +78 more
TL;DR: Codes for the primary tumor categories of AIS and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in part‐solid tumors for the eighth edition of the tumor, node, and metastasis classification of lung cancer are proposed.
Journal ArticleDOI

Assessment of Usefulness of Endobronchial Ultrasonography in Determination of Depth of Tracheobronchial Tumor Invasion

TL;DR: This method allows visualization of the laminar structure of the tracheobronchial wall, which is impossible with other diagnostic imaging methods.
Journal ArticleDOI

Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer.

TL;DR: It is found that serum Nectin-4 levels were significantly higher in NSCLC patients than in healthy volunteers and should be a new candidate serum and tissue biomarker, as well as a therapeutic target.